Glycogen storage disease type III: a mixed-methods study to assess the burden of disease.

conceptual model glycogen storage disease type III mixed methods qualitative research rare disease

Journal

Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143

Informations de publication

Date de publication:
2024
Historique:
received: 14 06 2023
accepted: 12 12 2023
medline: 10 1 2024
pubmed: 10 1 2024
entrez: 10 1 2024
Statut: epublish

Résumé

Glycogen storage disease type III (GSD III) is a rare inherited disorder that results from a glycogen debranching enzyme deficiency. The purpose of this research was to collect data on the signs, symptoms, and impacts of GSD III from the perspective of adult patients and caregivers of individuals with GSD III. Online survey and qualitative interviews. Following institutional review board approval, adult patients and caregivers of children with GSD III were recruited through advocacy networks and clinical sites. If eligible, participants were consented, screened, and sent a survey and/or participated in a 60-min interview. The survey and interview included questions about family history, diagnosis, signs and symptoms, impacts, and management of GSD III. Conceptual models were developed following the analysis of results. In all, 29 adults and 46 caregivers completed the online survey and/or the interviews with 73 survey and 19 interview respondents. Adults and caregivers reported digestive, musculoskeletal, growth and physical appearance, and cardiac signs and symptoms. Liver conditions were reported by most respondents (83%). Adults and caregivers frequently reported impacts such as difficulty keeping up with peers (77%) and difficulty exercising/difficulty with physical activity (53%). Hypoglycemia was frequently reported in both adults and children, with more than half reporting hospitalizations due to hypoglycemia. Caregivers focused on hypoglycemia when reporting signs/symptoms that most interfere with their child's life and prevention of hypoglycemia as a desired outcome for an effective therapy. Adults most often reported muscle weakness as a top interfering symptom and the most important goal of a potential therapy. Impacts were also reported in activities of daily living, cognitive, emotional, work/school, and sleep domains. Individuals with GSD III experience a broad spectrum of symptoms and disease impacts. There is an unmet need for therapies that improve metabolic control, reduce the burden of dietary management, reduce fatigue and liver problems, and improve muscle strength and function.

Sections du résumé

Background UNASSIGNED
Glycogen storage disease type III (GSD III) is a rare inherited disorder that results from a glycogen debranching enzyme deficiency.
Objectives UNASSIGNED
The purpose of this research was to collect data on the signs, symptoms, and impacts of GSD III from the perspective of adult patients and caregivers of individuals with GSD III.
Design UNASSIGNED
Online survey and qualitative interviews.
Methods UNASSIGNED
Following institutional review board approval, adult patients and caregivers of children with GSD III were recruited through advocacy networks and clinical sites. If eligible, participants were consented, screened, and sent a survey and/or participated in a 60-min interview. The survey and interview included questions about family history, diagnosis, signs and symptoms, impacts, and management of GSD III. Conceptual models were developed following the analysis of results.
Results UNASSIGNED
In all, 29 adults and 46 caregivers completed the online survey and/or the interviews with 73 survey and 19 interview respondents. Adults and caregivers reported digestive, musculoskeletal, growth and physical appearance, and cardiac signs and symptoms. Liver conditions were reported by most respondents (83%). Adults and caregivers frequently reported impacts such as difficulty keeping up with peers (77%) and difficulty exercising/difficulty with physical activity (53%). Hypoglycemia was frequently reported in both adults and children, with more than half reporting hospitalizations due to hypoglycemia. Caregivers focused on hypoglycemia when reporting signs/symptoms that most interfere with their child's life and prevention of hypoglycemia as a desired outcome for an effective therapy. Adults most often reported muscle weakness as a top interfering symptom and the most important goal of a potential therapy. Impacts were also reported in activities of daily living, cognitive, emotional, work/school, and sleep domains.
Conclusion UNASSIGNED
Individuals with GSD III experience a broad spectrum of symptoms and disease impacts. There is an unmet need for therapies that improve metabolic control, reduce the burden of dietary management, reduce fatigue and liver problems, and improve muscle strength and function.

Identifiants

pubmed: 38196773
doi: 10.1177/20420188231224233
pii: 10.1177_20420188231224233
pmc: PMC10775738
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20420188231224233

Informations de copyright

© The Author(s), 2024.

Auteurs

Ayla Evins (A)

Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949 USA.

Jill Mayhew (J)

Ultragenyx Pharmaceutical Inc., Novato, CA, USA.

Tricia Cimms (T)

Ultragenyx Pharmaceutical Inc., Novato, CA, USA.

Julie Whyte (J)

Endpoint Outcomes, A Lumanity Company, Boston, MA and Long Beach, CA, USA.

Kathy Vong (K)

Endpoint Outcomes, A Lumanity Company, Boston, MA and Long Beach, CA, USA.

Elizabeth Hribal (E)

Endpoint Outcomes, A Lumanity Company, Boston, MA and Long Beach, CA, USA.

Christopher J Evans (CJ)

Endpoint Outcomes, A Lumanity Company, Boston, MA and Long Beach, CA, USA.

Andrew Grimm (A)

Ultragenyx Pharmaceutical Inc., Novato, CA, USA.

Classifications MeSH